Prevention of osteoporosis should be considered before a bone break occurs, and many patients at risk for the chronic bone condition may benefit from pharmacologic options. "Most current guidelines ...

Medicare beneficiaries from high vs low SES counties were less likely to discontinue romosozumab during the COVID-19 lockdown.

On Monday, the Food and Drug Administration issued a new draft guidance that requires drug manufacturers to conduct long-term nonclinical bone quality studies for osteoporosis treatments. The agency ...

The Food and Drug Administration on Tuesday approved an osteoporosis drug that represents the first new treatment approach in nearly two decades — a strategy based on a rare gene mutation in people ...

March 16, 2012 — The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) today recommended that the osteoporosis drug strontium ranelate (Protelos/Osseor, Les ...

Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...

From left to right: Dr. Andrea Vethencourt (clinical researcher in the Transformation and Metastasis Group at IDIBELL and the CNIO, and oncologist at ICO); Dr. Eva González-Suarez (leader of the ...

The benefits of hormone replacement have been underappreciated, Dr. Marty Makary, the agency’s commissioner, said on Monday. Critics described evidence for the change as insufficient.